Mendus Logo

Mendus

Clinical-stage company developing immunotherapies to prevent tumor recurrence.

IMMU | ST

Overview

Corporate Details

ISIN(s):
SE0005003654 (+1 more)
LEI:
529900AFBGFR7ZB50J95
Country:
Sweden
Address:
Västra Trädgårdsgatan 15, 111 53 Stockholm

Description

Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 10:00
Kommuniké från extra bolagsstämma i Mendus AB (publ) den 16 december 2025
Swedish 122.8 KB
2025-12-16 10:00
Report from the Extraordinary General Meeting of Mendus AB (publ) on 16 Decembe…
English 123.2 KB
2025-11-28 08:00
Ändring av antalet aktier och röster i Mendus AB (publ)
Swedish 123.8 KB
2025-11-28 08:00
Change in number of shares and votes in Mendus AB (publ)
English 123.1 KB
2025-11-18 23:45
Kallelse till extra bolagsstämma i Mendus AB (publ)
Swedish 145.4 KB
2025-11-18 23:45
Notice of Extraordinary General Meeting in Mendus AB (publ)
English 147.5 KB
2025-11-18 23:41
Mendus har framgångsrikt genomfört en riktad nyemission om cirka 52,5 miljoner …
Swedish 151.0 KB
2025-11-18 23:41
Mendus announces successful execution of a directed share issue of approximatel…
English 150.6 KB
2025-11-18 17:31
Mendus avser att genomföra en riktad nyemission av aktier om cirka 50 miljoner …
Swedish 154.0 KB
2025-11-18 17:31
Mendus announces its intention to carry out a directed issue of shares of appro…
English 150.5 KB
2025-11-13 08:00 Swedish 1.5 MB
2025-11-13 08:00 English 1.5 MB
2025-11-06 08:00
Mendus Announces Nomination Committee for the 2026 Annual General Meeting
English 118.1 KB
2025-11-06 08:00
Mendus tillkännager valberedning inför årsstämman 2026
Swedish 118.2 KB
2025-10-02 08:00
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
Swedish 138.6 KB

Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mendus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mendus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Erik Manting Other Buy 7,780 56,249.40 SEK
2025-03-11 Erik Manting Other Buy 7,780 55,704.80 SEK
2025-02-25 Sven Arne Andreasson Other Buy 25,000 198,750.00 SEK
2024-04-02 Erik Manting Other Other 885,648 425,111.04 SEK
2024-04-02 Dharminder Chahal Other Other 882,048 423,383.04 SEK
2024-04-02 Leopold Bertea Other Other 267,858 128,571.84 SEK
2022-10-25 Sven Arne Andreasson Other Sell 15,000 31,950.00 SEK
2022-10-12 Sven Arne Andreasson Other Sell 10,000 18,800.00 SEK
2022-05-20 Erik Manting Other Buy 37,059 86,347.47 SEK
2022-05-19 Ann-Charlotte Ferm Other Buy 100,000 215,900.00 SEK

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.